Investors

To be an investor you must be a believer in a better tomorrow ~ Benjamin Graham

Hemera is a biotech company and an innovative start-up born with the aim of transforming scientific findings in the field of neuroregeneration into effective treatments, to bring research results to the patient bedside as soon as possible.

Hemera’s goal is to develop REMAST cell therapy as an advanced pharmacological product for the treatment of neurological lesions, transferring the therapy for spinal cord lesions conceived in the laboratories of the Universities of Verona and Milan into clinical practice.

Our ROADMAP

  • 2025

    2025

    2026

    2027

    2028

    2021

    2022

    2023

    2024

    Milestones

    2025

    • Grant of European Patent
    • Freedom To Operate
    • Initiation of preclinical studies on the route of administration
    • Development of the therapy for clinical use in compliance with GMP (IMPD)
    • Progression of the Observational Clinical Study
  • 2026

    2026

    2027

    2028

    2021

    2022

    2023

    2024

    2025

    Milestones

    2026

    • EMA Scientific Advice
    • Data collection for the Investigator’s Brochure (IB) of the REMaST therapy for subacute spinal cord injury
    • Protocol writing for the Phase I first-in-human interventional clinical trial
    • Data collection for the Investigational Medicinal Product Dossier (IMPD) of the REMaST therapy for subacute spinal cord injury
    • Development of a minimally invasive system for customized REMaST administration in collaboration with an industrial partner
    • Progression of the Observational Clinical Study
  • 2027

    2027

    2028

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2027

    • EMA approval of the interventional clinical study
    • Initiation of the Phase 1b/2a first-in-human interventional clinical study
    • Initiation of preclinical studies for validation of frozen REMaST
  • 2028

    2028

    2021

    2022

    2023

    2024

    2025

    2026

    2027

    Milestones

    2028

    • Conclusion of the Phase 1b first-in-human interventional clinical study
    • Final Report of the Phase 1b Clinical Study (Safety and Dosage)
    • Initiation of the PRIME Program
    • Application for Conditional Marketing Authorization
  • 2021

    2021

    2022

    2023

    2024

    2025

    2026

    2027

    2028

    Milestones

    2021

    • Filing of the Italian patent application
    • Company incorporation
    • Recognition as a spinoff of the University of Verona and the University of Milan
    • Establishment of the Regulatory & Advisory Board
    • Selection of initial strategic partners
    • Capital raise of €750,000
  • 2022

    2022

    2023

    2024

    2025

    2026

    2027

    2028

    Milestones

    2022

    • International extension of the patent application
    • Definition of the minimally invasive route of administration
    • Activation of the neurosurgery and neurorehabilitation network
    • Establishment of the Clinical Board
    • EMA classification as an Advanced Therapy Medicinal Product (ATMP)
    • Definition of the protocol for the prospective observational study
    • Organizational development: implementation of operational management structures
    • Initial production tests of the therapy for clinical use
    • Capital raise of €1.5 million
  • 2023

    2023

    2024

    2025

    2026

    2027

    2028

    2021

    2022

    Milestones

    2023

    • Grant of the Italian Patent
    • EMA Orphan Drug Designation
    • Efficacy testing of the therapy’s delivery technique
    • International patent coverage in individual countries
    • Scientific publication in high-impact journals
    • Recruitment of 15 patients for the prospective observational study
    • Cell therapy production in a closed-loop system
    • Fundraising
  • 2024

    2024

    2025

    2026

    2027

    2028

    2021

    2022

    2023

    Milestones

    2024

    • EMA Scientific Advice
    • Design of the in vivo human study
    • Creation of a network of industrial and strategic collaborations
    • Follow-up of the Observational Study
    • Fundraising
    • Clinical Synopsis writing

Fundraising according to Hemera

A new democratic form of investment aimed at raising the required capital from anyone who is interested in the development of new therapies for very disabling diseases and is looking for a truly socially responsible investment.

Since its foundation, in May 2021, the company has raised over 2 million euros.

In the first 18 months of the company’s life, 1 Family Office and over 100 business angels, private investors, and companies – who organized themselves into two investment syndicates called Friends of Founders S.r.l. and Proemera S.r.l. – invested in Hemera.